Crispr Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Oppenheimer lifted their FY2019 EPS estimates for shares of Crispr Therapeutics in a report issued on Monday, November 25th, according to Zacks Investment Research. Oppenheimer analyst S. Tuerkcan now expects that the company will post earnings per share of $0.59 for the year, up from their prior forecast of $0.58. Oppenheimer currently has a “Outperform” rating and a $80.00 target price on the stock.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million.

Other analysts have also recently issued reports about the stock. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Roth Capital raised their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group upped their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, BidaskClub downgraded Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $69.54.

Shares of Crispr Therapeutics stock traded up $2.92 during midday trading on Wednesday, hitting $68.06. The company had a trading volume of 1,017,171 shares, compared to its average volume of 1,114,405. The company has a 50 day moving average of $62.13 and a 200 day moving average of $49.47. The stock has a market capitalization of $3.60 billion, a P/E ratio of -19.78 and a beta of 3.31. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.

A number of hedge funds have recently modified their holdings of the business. NEXT Financial Group Inc increased its position in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after buying an additional 549 shares in the last quarter. Benjamin Edwards Inc. boosted its position in Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at about $26,000. US Bancorp DE grew its stake in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after acquiring an additional 526 shares in the last quarter. Finally, BSW Wealth Partners purchased a new stake in Crispr Therapeutics during the 2nd quarter valued at about $39,000. Institutional investors own 49.82% of the company’s stock.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at approximately $412,500. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 in the last three months. Corporate insiders own 21.40% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What is meant by a buy rating?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link